| 1 |
33792220 | Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. | 2022 Mar 1 |
2 |
| 2 |
34326465 | Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. | 2022 Jan |
2 |
| 3 |
34644371 | Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition. | 2022 Jan 25 |
1 |
| 4 |
34724284 | Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation. | 2022 Jan |
1 |
| 5 |
34767056 | Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre. | 2022 Jan |
1 |
| 6 |
34903489 | State-of-the-Art Review on Myelofibrosis Therapies. | 2022 May |
4 |
| 7 |
35264503 | [Molecular pathogenesis and therapeutic targets in acute erythroid leukemia]. | 2022 |
1 |
| 8 |
35368221 | A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis. | 2022 May |
2 |
| 9 |
35368384 | Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2022 May |
2 |
| 10 |
35434097 | Turner syndrome with primary myelofibrosis, cirrhosis and ovarian cystic mass: A case report. | 2022 Mar 26 |
1 |
| 11 |
35437311 | Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. | 2022 Jun |
1 |
| 12 |
35635540 | Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis. | 2022 Jun 16 |
2 |
| 13 |
32814839 | Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. | 2021 Apr |
1 |
| 14 |
33052714 | Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension. | 2021 Jan |
2 |
| 15 |
33129109 | Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. | 2021 Jan |
1 |
| 16 |
33222197 | Second primary malignancy in myelofibrosis patients treated with ruxolitinib. | 2021 Apr |
2 |
| 17 |
33243417 | [Myelofibrosis: A review]. | 2021 Feb |
1 |
| 18 |
33338537 | JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. | 2021 Jun |
1 |
| 19 |
33413168 | Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review. | 2021 Jan 7 |
1 |
| 20 |
33502001 | Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene. | 2021 Feb |
1 |
| 21 |
33503434 | Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. | 2021 Jan 26 |
1 |
| 22 |
33570945 | Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. | 2021 Feb 25 |
1 |
| 23 |
33782031 | Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. | 2021 Jun 15 |
2 |
| 24 |
33845867 | Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. | 2021 Apr 12 |
2 |
| 25 |
33936902 | Advances in the Treatment of Polycythemia Vera: Trends in Disease Management. | 2021 Mar 30 |
1 |
| 26 |
33954282 | Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models. | 2021 May |
1 |
| 27 |
33965175 | Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells. | 2021 May |
1 |
| 28 |
33982267 | Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. | 2021 Jul |
1 |
| 29 |
33994432 | Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2V617F-myeloproliferative neoplasm. | 2021 Jun 5 |
2 |
| 30 |
34016786 | Integrated bioinformatic analysis reveals the underlying molecular mechanism of and potential drugs for pulmonary arterial hypertension. | 2021 May 18 |
1 |
| 31 |
34068690 | Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. | 2021 May 10 |
2 |
| 32 |
34140953 | Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms. | 2021 |
1 |
| 33 |
34169393 | Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. | 2021 Aug |
1 |
| 34 |
34260836 | Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. | 2021 Jul 15 |
1 |
| 35 |
34324169 | Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation. | 2021 Sep |
2 |
| 36 |
34367701 | Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm. | 2021 |
1 |
| 37 |
34376782 | Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia. | 2021 Aug 10 |
2 |
| 38 |
34496019 | A novel activating JAK1 mutation in chronic eosinophilic leukemia. | 2021 Sep 28 |
1 |
| 39 |
34505882 | Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. | 2021 Sep 14 |
1 |
| 40 |
34520107 | Efficacy and safety of ruxolitinib in ineffective erythropoiesis suppression as a pretransplantation treatment for pediatric patients with beta-thalassemia major. | 2021 Nov |
1 |
| 41 |
34547879 | [Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report]. | 2021 Aug 14 |
1 |
| 42 |
34623777 | Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis. | 2021 Sep |
1 |
| 43 |
34638347 | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. | 2021 Sep 28 |
1 |
| 44 |
34707996 | Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review. | 2021 |
2 |
| 45 |
34871267 | Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report. | 2021 Nov 5 |
2 |
| 46 |
34875179 | Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials. | 2021 Dec |
1 |
| 47 |
34882211 | Degrading JAK2 in ALL by ruxolitinib-based PROTACs. | 2021 Dec 9 |
1 |
| 48 |
31227936 | Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. | 2020 Jun |
1 |
| 49 |
31286322 | Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. | 2020 Jun |
1 |
| 50 |
31452174 | Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regulating JAK/STAT Pathway. | 2020 |
4 |